GlassScriptPhysician profile
Derick Reedy
NPI 1427684562
$23,202.33
in general payments reported to CMS, 2019-2025
14 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.15 · 2024: $1,080 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $4,130 · Food and Beverage: $4,022 · Education: $80.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,952.00 |
| Travel and Lodging | $4,130.19 |
| Food and Beverage | $4,022.29 |
| Education | $80.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15,468.55 | 2024-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $5,625.26 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $735.70 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $328.89 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $319.88 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $187.20 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $152.25 | 2024-2025 | Aristada, Aristada Initio, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $150.18 | 2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $125.18 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $38.60 | 2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $24.61 | 2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $17.15 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.45 | 2025 | Quviviq |
| Neos Therapeutics, LP | $14.43 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derick Reedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.